Bukwang, BMS Korea set to challenge GSK's hepatitis B medicines in second quarter
Published: 2008-02-26 06:59:00
Updated: 2008-02-26 06:59:00
Domestic hepatitis B market is heating up as Bukwang Pharm's Levovir (clevudine) and BMS Korea's Baraclude (entecavir) are poised to snatch up a large share of GlaxoSmithKline's Zeffix (lamivudine) and Hepsera (adefovir) in the second quarter of this year, according to sources.
The domestic an...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
